MMATORY PARAMETERS ANALYSIS IN SEVERE COVID-19 PATIENTS TREATED WITH TOCILIZUMAB
4CPS-330
INDIVIDUALISING THERAPIES THROUGH PHARMACOKINETICS: ADALIMUMAB FOR INFLAMMATORY BOWEL DISEASE
4CPS-329
DO PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES THINK THEY KNOW THEIR MEDICATION?
4CPS-328
BIOLOGICAL DRUGS FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS: ANALYSIS ACCORDING TO THE MECHANISM OF ACTION
4CPS-327
EFFECTIVENESS, SAFETY AND ADHERENCE OF BARICITINIB AND TOFACITINIB IN RHEUMATOID ARTHRITIS
4CPS-326
ADALIMUMAB’S PERSISTENCE IN RHEUMATHOLOGICAL DISEASES
4CPS-325
EFFECTS ON ADHERENCE IN PATIENTS WITH ARTHROPATHIES CHANGING TREATMENT
4CPS-324
EFFECTIVENESS AND SAFETY OF IXEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS
4CPS-323
EVALUATION OF THE USE, ADHERENCE AND TOLERANCE OF 0.03% TACROLIMUS EYE DROPS
4CPS-322
ADALIMUMAB CONCENTRATIONS PRIOR TO THE IMPLEMENTATION OF THERAPEUTIC DRUG MONITORING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
4CPS-321
ANAKINRA IN SEVERE COVID-19 PNEUMONIA: RETROSPECTIVE STUDY
4CPS-320
IMPROVING MEDICATION ADHERENCE AND PATIENTS’ EXPERIENCE AFTER HEART TRANSPLANT USING A MULTILEVEL eHEALTH INTERVENTION: THE mHEART CLINICAL TRIAL
4CPS-319
PIRFENIDONE AND NINTEDANIB FOR THE TREATMENT OF THE IDIOPATHIC PULMONARY FIBROSIS: AN ITALIAN HOSPITAL EXPERIENCE
4CPS-318
COMPOUNDING TACROLIMUS OPHTHALMIC OINTMENT 0,02% IN THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE OPHTHALMIC SYNDROMES: EFFECTIVENESS AND SAFETY ASSESSMENT
4CPS-317
IMMUNOSUPPRESSIVE TREATMENT MANAGEMENT IN A COHORT OF HOSPITALIZED SOLID ORGAN RECIPIENTS AFFECTED BY COVID-19
